Physician profile
Christopher Eing Wee
NPI 1225457583
$37,586.18
in general payments reported to CMS, 2019-2025
11 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $9,497 · 2023: $1,363 · 2024: $16K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,800 · Travel and Lodging: $2,509 · Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,098.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,800.00 |
| Travel and Lodging | $2,509.10 |
| Food and Beverage | $1,411.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14,601.38 | 2022-2024 | |
| Janssen Biotech, INC. | $10,923.89 | 2022-2025 | Erleada, Akeega |
| Pfizer INC. | $10,523.77 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $817.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $217.19 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Esteve Pharmaceuticals LLC | $145.00 | 2025 | Lysodren |
| Exelixis INC. | $133.64 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $73.81 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.